---
title: "Crown Material: Expected net loss of 60 million to 80 million yuan in 2024"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/225348142.md"
description: "Crown Material expects a net profit loss of 60 million to 80 million yuan in 2024, with operating revenue of 850 million to 870 million yuan, a year-on-year decrease of 37.69% to 39.12%. Compared to the same period last year, the net profit decreased by 36.1246 million to 56.1246 million yuan, a year-on-year decrease of 151.30% to 235.07%. The net profit after deducting non-recurring gains and losses is expected to be -85 million to -65 million yuan, a year-on-year decrease of 81.24% to 137.00%"
datetime: "2025-01-17T12:08:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/225348142.md)
  - [en](https://longbridge.com/en/news/225348142.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/225348142.md)
---

# Crown Material: Expected net loss of 60 million to 80 million yuan in 2024

Crown Material announced that it expects to achieve an annual operating revenue of 850 million to 870 million yuan in 2024, a decrease of 526 million to 546 million yuan compared to the same period last year, representing a year-on-year decrease of 37.69% to 39.12%. It is expected that the net profit attributable to the owners of the parent company for the year 2024 will be -80 million to -60 million yuan, a decrease of 36.1246 million to 56.1246 million yuan compared to the same period last year, representing a year-on-year decrease of 151.30% to 235.07%. It is expected that the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses for the year 2024 will be -85 million to -65 million yuan, a decrease of 29.1357 million to 49.1357 million yuan compared to the same period last year, representing a year-on-year decrease of 81.24% to 137.00%

### Related Stocks

- [688560.CN](https://longbridge.com/en/quote/688560.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [CMOC Group (CMCLF): New Buy Recommendation for This Basic Materials Giant](https://longbridge.com/en/news/286625840.md)
- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)
- [11:23 ETTOUS les JOURS BRINGS OFFICIAL BTS THE CITY ARIRANG POP-UP EXPERIENCE TO LAS VEGAS BAKERY CAFÉS](https://longbridge.com/en/news/286793282.md)
- [Cagent Vascular closes oversubscribed $41 million Series D financing round](https://longbridge.com/en/news/287114819.md)